An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Apitolisib (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Jun 2012 Actual patient number is 42 according to ClinicalTrials.gov record.
- 19 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.